Table 1.
Patients’ characteristics.
| Variables | iCCA (n = 162) |
| Demographics | |
| Gender, M/F (%) | 76 (46.9)/86 (53.1) |
| Age (years) | 66 (58–74) |
| ASA, n (%) | |
| I | 4 (2.5) |
| II | 64 (39.5) |
| III | 87 (53.7) |
| IV | 7 (4.3) |
| V | 0 (0) |
| Cholangitis, n (%) | 10 (6.2) |
| Portal vein embolization, n (%) | 14 (8.6) |
| Preoperative chemotherapy, n (%) | 21 (13.0) |
| Clinical chemistry | |
| AST (U/L) | 33.0 (25.0–46.0) |
| ALT (U/L) | 27.0 (18.0–48.0) |
| Albumin (g/L) | 4.3 (4.0–4.6) |
| AP, U/L | 118.0 (85.5–217.0) |
| CA199 (U/mL) | 55.20 (20.00–274.40) |
| CRP (mg/L) | 55.20 (20.00–274.40) |
| GGT (U/L) | 109.0 (55.5–299.0) |
| Hemoglobin (g/dL) | 13.0 (12.00–14.20) |
| INR | 1.00 (0.96–1.07) |
| Platelet count (/nL) | 247 (193–306) |
| Prothrombin time (%) | 100 (89–107) |
| Total bilirubin (mg/dL) | 0.46 (0.335–0.690) |
| Operative Data | |
| Intraoperative PRBC, n (%) | 48 (29.6) |
| Intraoperative FFP, n (%) | 56 (34.6) |
| Operative time (minutes) | 300 (230–362) |
| Operative procedure, n (%) | |
| Bisegmentectomy | 23 (14.1) |
| Hemihepatectomy | 57 (35.0) |
| Extended hemihepatectomy | 31 (19.0) |
| Trisectionectomy | 20 (12.3) |
| Hepatoduodenoectomy | 0 (0) |
| ALPPS | 14 (8.6) |
| Others | 18 (11.0) |
| Time to surgery, days | 47 (30–89) |
| Pathological examination | |
| LVI, n (%) | 33 (20.4) |
| MVI, n (%) | 52 (32.1) |
| R1 resection, n (%) | 16 (9.9) |
| pT category n (%) | |
| 1 | 58 (35.8) |
| 2 | 62 (38.3) |
| 3 | 24 (14.8) |
| 4 | 17 (10.5) |
| pN category, n (%) | |
| N0 | 91 (56.2) |
| N1 | 57 (35.2) |
| Tumor grading, n (%) | |
| G1 | 2 (1.2) |
| G2 | 94 (58.0) |
| G3 | 42 (25.9) |
| G4 | 5 (3.1) |
| Postoperative Data | |
| Intensive care, days | 1 (1–1) |
| Hospitalization, days | 13 (8–26) |
| Postoperative complications, n (%) | |
| No complications | 56 (34.6) |
| Clavien–Dindo I | 8 (4.9) |
| Clavien–Dindo II | 30 (18.5) |
| Clavien–Dindo IIIa | 34 (20.9) |
| Clavien–Dindo IIIb | 13 (8.0) |
| Clavien–Dindo IVa | 8 (5.0) |
| Clavien–Dindo IVb | 1 (0.6) |
| Clavien–Dindo V | 12 (7.4) |
| Liver failure, n (%) | |
| No failure | 135 (82.8) |
| Grade A | 13 (8.0) |
| Grade B | 8 (4.9) |
| Grade C | 7 (4.3) |
| Infection Clavien–Dindo | |
| No complications | 89 (54.6) |
| Clavien–Dindo I | 0 (0) |
| Clavien–Dindo II | 30 (18.4) |
| Clavien–Dindo IIIa | 30 (18.4) |
| Clavien–Dindo IIIb | 4 (2.5) |
| Clavien–Dindo IVa | 0 (0) |
| Clavien–Dindo IVb | 1 (0.6) |
| Clavien–Dindo V | 8 (4.9) |
| Bile leak, n (%) | |
| No | 134 (82.2) |
| Grade A | 3 (1.8) |
| Grade B | 20 (12.3) |
| Grade C | 6 (3.7) |
| Hemorrhage, n (%) | |
| No | 150 (92.0) |
| Grade A | 2 (1.2) |
| Grade B | 2 (1.2) |
| Grade C | 9 (5.5) |
| Oncologic Data | |
| Adjuvant chemotherapy, n (%) | 56 (34.6) |
| Recurrence, n (%) | 95 (58.6) |
| Median RFS, months (95% CI) | 12 (8–16) |
| Median OS, months (95% CI) | 22 (17–28) |
| Body composition | |
| BMI (kg/m2) | 25.35 (22.61–29.27) |
| Visceral_fat area (cm2) | 131.82 (64.67–216.76) |
| SMI (cm2/m2) | 43.27 (38.93–50.24) |
| SM-RA (HU) | 37.06 (28.97–41.72) |
| Obesity, n (%) | 86 (53.1) |
| Sarcopenia, n (%) | 103 (63.2) |
| Myosteatosis, n (%) | 86 (52.8) |
| Visceral obesity, n (%) | 101 (62.3) |
| Sarcopenic_obesity, n (%) | 25 (15.3) |
Note: Data are presented as median and interquartile range if not noted otherwise. ALPPS, associating liver partition with portal vein ligation for staged hepatectomy; ASA, American Society of Anesthesiology; AP, alkaline phosphatase; BMI, body mass index; CI, confidence interval; F, female; FFP, fresh frozen plasma; LVI, lymph vascular invasion; M, male; MVI, microvascular invasion; OS, overall survival; RFS, recurrence-free survival; SMI, skeletal muscle index; SM-RA, skeletal muscle radiation attenuation.